Cgm Dexcom denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cgm dexcom are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Dexcom CGM as Experimental

An "experimental or investigational" denial from UnitedHealthcare means UHC's coverage policy determined that the Dexcom CGM system — or the specific use for which it was prescribed — does not meet the plan's criteria for established clinical benefit. This denial type is particularly frustrating because Dexcom devices carry FDA clearance for continuous glucose monitoring; however, UHC's internal medical policy may impose additional evidence standards beyond FDA clearance, or may restrict coverage to particular patient populations it has defined as having established benefit. The denial may reflect a policy application to your specific clinical circumstances rather than a blanket experimental classification.

## Why This Denial Is Appealable

ACA §2719 requires non-grandfathered plans to provide internal appeals and access to independent external review by a certified independent review organization (IRO). External review of experimental/investigational denials is specifically contemplated under federal law. ERISA §503 applies to employer-sponsored plans. You have approximately 180 days from the denial to file your first internal appeal and approximately four months from the final internal denial to request external review. Expedited review is available when a delay would seriously jeopardize your health. External review is especially powerful for experimental denials because an independent clinical reviewer — not UHC — makes the final determination.

## The Appeal Process

1. Obtain UHC's exact experimental/investigational criteria. Request the specific UHC medical policy applied and the criteria your case allegedly failed to meet. 2. Identify professional society support. Relevant guideline organizations (such as the ADA for diabetes management) have issued guidance on CGM use; your prescriber can reference the applicable guideline organization generically to establish that CGM is within mainstream clinical practice for your condition. 3. File a Level 1 internal appeal with a full clinical package. 4. File a Level 2 internal appeal if Level 1 is upheld. 5. Request external review — this is the highest-leverage step for experimental denials, because the IRO's clinical reviewers evaluate whether UHC's experimental determination is clinically justified.

## Documentation to Gather

• FDA labeling for Dexcom: Confirms the device's cleared status and approved indications.
• Prescriber letter: Should explain why CGM is established, not experimental, for your specific clinical circumstance, referencing the applicable professional society guidance organization.
• Clinical guideline references: Your provider should note (without citing specific numbers) that the relevant diabetes management guidelines address CGM use for your patient population.
• Diagnosis and clinical severity documentation: Chart notes establishing the clinical basis for the prescription.

## Criteria-Mapping Structure

Request UHC's experimental/investigational coverage policy criteria. Map each criterion to the specific clinical documentation and labeling reference that satisfies it. For the "experimental" label specifically, the most powerful counter-evidence is the combination of FDA clearance, mainstream professional society endorsement, and your prescriber's clinical judgment — all documented explicitly and linked to your individual case.